NULIBRY™ (fosdenopterin)
Approved for Use in the U.S.
Caregivers and healthcare providers, learn more at nulibry.com.
In 2022, Sentynl Therapeutics, Inc. acquired global rights to NULIBRY and is responsible for the ongoing development and commercialization of NULIBRY in the U.S. and developing, manufacturing and commercializing fosdenopterin globally.
TRUSELTIQ™ (infigratinib)
Approved for Use in the U.S., Canada and Australia.
U.S. patients and healthcare providers, learn more at truseltiq.com.
Personalized support program for patients receiving Truseltiq.
In 2022, Helsinn Group gained an exclusive license to commercialize infigratinib in oncology indications in the U.S. and is responsible for developing, manufacturing and commercializing infigratinib in oncology indications worldwide except in mainland China, Hong Kong and Macau.
our products
It is our mission to develop transformative medicines to treat patients who suffer from genetic diseases and cancers with clear genetic drivers. We prioritize focused execution to reach patients in need of options quickly while also strategically advancing high-quality programs in our pipeline. Every approved product from BridgeBio represents our commitment to delivering hope through rigorous science.